Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | RECQL | P46063 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.54 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.54 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.54 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | GGT1 | P19440 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390528 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL29135334 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL28956887 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL725982 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL6328818 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL727072 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL16800398 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL44212 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL1858148 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL10697059 | 1.00 | KDM4E (0.88) | KDM4EMEN1KMT2ARECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113226470-A | Rifamycin analogs and antibody-drug conjugates thereof | 瑞泽恩制药公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20150374839-A1 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES | KEAN UNIVERSITY (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374839-A1 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES | KEAN UNIVERSITY (US) | 2015-12-31 | — | — | US | disclosed |
| US-9056139-B2 | Fatty acid-salicylate conjugates with enhanced therapeutic properties | KEAN UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056139-B2 | Fatty acid-salicylate conjugates with enhanced therapeutic properties | KEAN UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-6368615-B1 | POLYMER OF UNSATURATED ESTER OF SALICYLIC ACID | GUTTAG ALVIN (US) | 2002-04-09 | — | — | US | disclosed |
| US-6037338-A | AND REDUCING RISK OF HEART ATTACKS | GUTTAG ALVIN (US) | 2000-03-14 | — | — | US | disclosed |
| US-5910511-A | ALTERNATIVE TO ASPIRIN WHICH HAS LESSER UNDESIRABLE SIDE EFFECTS | GUTTAG ALVIN (US) | 1999-06-08 | — | — | US | disclosed |
| US-5760261-A | ANTINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECTREDUCTION | GUTTAG ALVIN (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0275203-A2 | Heat-sensitive recording material containing color forming components | FUJI PHOTO FILM CO., LTD. (JP) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374839-A1 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES | FASN, ELOVL1, ELOVL3 | KDM4E 2152/4885MEN1 4457/4885KMT2A 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.